Alzheon, Inc. Employee Directory
Biotechnology ResearchMassachusetts, United States11-50 Employees
Alzheon, Inc. is a biotechnology research company based in Framingham, Massachusetts, with 11-50 employees. The company focuses on developing medicines for neurodegenerative disorders, led by ALZ-801, an oral prodrug of tramiprosate intended to block formation of neurotoxic soluble amyloid oligomers in the brain. ALZ-801 aims to leverage a precision medicine approach that uses individual genetic and biological information to guide therapy development. The company has presented biomarker data from its APOLLOE4 Phase III trial and related studies at scientific conferences in 2025-2026. It has undertaken funding and governance activity, including a $100 million Series E in 2024 and the appointment of new board members.